INCHEON, South Korea, December 18 /PRNewswire/ --
Celltrion, Inc., a leading Korean biopharmaceutical company, announces that it has received approval from the U.S. Food and Drug Administration (FDA) to serve as a contract manufacturer to produce ORENCIA(R) (abatacept), a novel biologic agent for the treatment of rheumatoid arthritis, developed by Bristol-Myers Squibb Company (NYSE: BMY). The Supplemental Biological License Application (sBLA) was submitted by Bristol-Myers Squibb Company to meet expected long-term demand for ORENCIA(R).
Celltrion is the largest biopharmaceutical manufacturing facility in the Asia-Pacific region, and the only Asian large-scale cell-culture contract manufacturing facility which has successfully obtained approval from the U.S. FDA.